Market revenue in 2022 | USD 1,976.0 million |
Market revenue in 2030 | USD 12,950.8 million |
Growth rate | 26.5% (CAGR from 2022 to 2030) |
Largest segment | Cell therapy |
Fastest growing segment | Gene Therapy |
Historical data covered | 2018 - 2021 |
Base year for estimation | 2022 |
Forecast period covered | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Gene Therapy, Cell Therapy |
Key market players worldwide | Lonza Group Ltd, Bluebird bio Inc, Catalent Inc, Roche, Samsung BioLogics, Boehringer Ingelheim, Hitachi Ltd, Takara Bio Inc, Miltenyi Biotec, Thermo Fisher Scientific Inc, Novartis AG ADR, Merck KGaA, Wuxi AppTec Co Ltd |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy manufacturing market will help companies and investors design strategic landscapes.
Cell therapy was the largest segment with a revenue share of 60.28% in 2022. Horizon Databook has segmented the Europe cell and gene therapy manufacturing market based on gene therapy, cell therapy covering the revenue growth of each sub-segment from 2018 to 2030.
Growing investments on gene & cell therapy companies across European countries is a major driving factor for cell and gene therapy manufacturing market in the European region. Process development and manufacturing for gene & cell therapies are growing at a constant pace in Europe.
Moreover, the European region is at the forefront in terms of providing funds for development and commercialization of cell & gene therapy products as well as R&D activities. For instance, in January 2019, an international research team received funding of approximately USD 7.7 million from the European Union under the Horizon 2020 research & innovation program for the development of nonviral gene delivery technology.
In addition, apceth Biopharma GmbH and Hitachi Chemical Advanced Therapeutic solutions signed an agreement with Bluebird Bio in May 2020 for the expansion of production capacity for Lenti-D for CALD. Such initiatives are anticipated to accelerate market growth in the region.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe cell and gene therapy manufacturing market , including forecasts for subscribers. This continent databook contains high-level insights into Europe cell and gene therapy manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account